SLC5A2 and diabetic kidney disease: However, because these studies excluded patients with eGFR of 25–30 mL/min/1.73 m2 or less and furthermore, in the present study, SGLT2 inhibitors were not widely used, so it is not clear whether these agents will improve the cardiovascular outcomes in patients with advanced stages of DKD.